Precision Metabolic Rewiring for Industrial-Scale High-Value Chemical Production. Escherichia coli is the premier workhorse of modern industrial biotechnology. However, achieving commercially viable titers for complex molecules requires more than single-gene edits—it demands the systemic redirection of metabolic flux. CD Biosynsis provides professional E. coli Multi-Gene Knockout Strain Construction Services, utilizing advanced CRISPR/Cas9, Cas12a, and CRISPRi platforms. We enable the simultaneous deactivation of multiple gene targets and the fine-tuning of metabolic pathways to empower the rapid development of microbial cell factories for amino acids, biofuels, and high-value chemicals.
Get a Technical QuoteOur platform integrates computational modeling with cutting-edge CRISPR toolkits to transform E. coli into a high-performance production host. We focus on maximizing carbon flux toward your target molecule while maintaining optimal host fitness.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| Multiplex Gene Knockout | CRISPR/Cas9 Multi-target System | Eliminating competitive pathways (e.g., ackA-pta, ldhA) | Verified multi-null mutants + Sequencing data |
| Metabolic Rewiring | CRISPR/Cas12a (Cpf1) Integration | Synthetic pathway assembly (e.g., 1,4-BDO) | Engineered production strains + Titer analysis |
| Dynamic Gene Regulation | CRISPRi (Interference) | Downregulating essential genes without growth loss | Tuning strains + qPCR expression reports |
| Flux Optimization | Metabolic Flux Analysis (MFA) | Identifying optimal knockout & integration targets | Integrated modeling report + Prediction data |
1. In Silico Design & Modeling
2. CRISPR System Selection
3. Genome Execution
4. Validation & Delivery
Utilizing Metabolic Flux Analysis (MFA) to identify competitive pathways and predict the most impactful knockout strategy.
Formal project proposal and Mutual NDA signing.
Choosing between Cas9 (for deep knockouts) or Cas12a (for high-efficiency multiplexing) based on target quantity.
Optimization of gRNA arrays for simultaneous multi-locus targeting.
Simultaneous transformation and selection of multi-gene edits, including scarless deletions and pathway integrations.
Tuning of expression intensity using CRISPRi for essential pathway nodes.
Final verification of genetic structure via Sanger/WGS and phenotypic characterization of titers under simulated industrial conditions.
Final delivery of optimized "cell factory" strains and comprehensive data reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. These studies demonstrate the power of multiplexed genome rewiring.
Achieving high-titer production of chemicals like L-phenylalanine requires the total elimination of competitive routes. Research has demonstrated that utilizing CRISPR/Cas9 to simultaneously knockout multiple genes (e.g., ackA-pta, adhE, ldhA) effectively redirects carbon flux toward the target product. When combined with metabolic flux analysis, these engineered strains show significantly enhanced production potential.
(Reference: Li X. et al., Metabolic Engineering, 2024)
The transition from lab-scale to industrial production of plastic precursors like 1,4-BDO requires complex genomic overhauls. Technical benchmarks utilizing CRISPR/Cas12a (Cpf1) showcase the ability to perform multiplexed editing—knocking out inhibitory genes while simultaneously integrating heterologous metabolic pathways. This allows for the rapid advancement of biosynthetic capabilities to industrial fermentation standards.
(Reference: Wang Y. et al., Nature Communications, 2022)
In many pathways, permanent knockouts of key genes result in severe growth defects. Reversible gene regulation using CRISPRi allows for the fine-tuned downregulation of multiple genes at the transcriptional level. By adjusting expression intensity without permanent genomic loss, research has achieved significant increases in L-methionine yields, providing a flexible alternative for industrial strain development.
(Reference: Zhang L. et al., Biotechnology for Biofuels, 2021)
Developing strains for efficient biofuel production involves extensive modification of fatty acid synthesis pathways. Utilizing the high multiplexing efficiency of CRISPR/Cas12a, researchers have successfully performed multi-site gene knockouts to optimize these pathways. This benchmark highlights the potential of Cas12a for high-throughput genome editing in the pursuit of sustainable energy solutions.
(Reference: Liu Q. et al., Applied Microbiology and Biotechnology, 2023)
Ready to rewire your industrial production strain?
Contact Us1. Why use CRISPR/Cas12a instead of Cas9 for my project?
Cas12a (Cpf1) is particularly effective for multiplexing because it processes its own crRNA arrays. This allows us to target multiple genes (3-6 targets) simultaneously with higher efficiency and simplicity in E. coli.
2. Can you perform knockouts in proprietary industrial E. coli strains?
Yes. We have extensive experience adapting our CRISPR toolkits to various industrial backgrounds. We can work under strict NDAs to optimize your specific proprietary strains for commercial production.
3. How do you handle essential genes that cannot be completely knocked out?
For genes critical for survival but competing with your pathway, we recommend CRISPRi. This allows us to "knock down" expression to a low level, redirecting flux without killing the host cell.
4. What is the typical turnaround time for a 3-4 gene knockout project?
A standard project—including modeling, genomic execution, and validation—typically takes 6 to 10 weeks, depending on the complexity of the metabolic pathway.
5. How do you verify the final multi-gene knockout strain?
We perform junction PCR to confirm the loss of wild-type alleles at every target locus and provide Sanger or Whole Genome Sequencing (WGS) data to ensure 100% accuracy.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.